Get the Stockscreener App
2.74
0.36%
-0.010
Orchestra Biomed Holdings Inc stock is traded at $2.74, with a volume of 247.61K.
It is down -0.36% in the last 24 hours and down -22.16% over the past month.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
See More
Previous Close:
$2.75
Open:
$2.77
24h Volume:
247.61K
Relative Volume:
0.80
Market Cap:
$106.51M
Revenue:
$2.76M
Net Income/Loss:
$-49.12M
P/E Ratio:
-1.8267
EPS:
-1.5
Net Cash Flow:
$-46.21M
1W Performance:
-1.44%
1M Performance:
-22.16%
6M Performance:
-48.20%
1Y Performance:
-50.63%
1-Day Range:
$2.71
$2.84
1-Week Range:
$2.43
$3.12
52-Week Range:
$2.43
$8.8699
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
2.74 | 106.51M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | BTIG Research | Buy |
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
OBIO: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
How did Orchestra BioMed Holdings Inc (OBIO) fare last session? - uspostnews.com
Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment - MyChesCo
Orchestra Biomed sees $149,201 stock purchase by RTW Investments By Investing.com - Investing.com Australia
Orchestra BioMed Holdings Inc [OBIO] Records 200-Day SMA of $5.25 - knoxdaily.com
Orchestra BioMed to Present at Jefferies Global Healthcare Conference - MyChesCo
Geode Capital Management LLC Boosts Stock Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
FDA approves head-to-head trial of Orchestra BioMed’s balloon - Investing.com
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy - Diagnostic and Interventional Cardiology
FDA Clears Orchestra BioMed's Virtue SAB Trial To Treat Coronary ISR - Nasdaq
Orchestra BioMed (OBIO) Gains FDA Nod for Updated Coronary ISR T - GuruFocus
Orchestra BioMed Receives FDA Approval for IDE Amendment - TipRanks
Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon - marketscreener.com
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon - GlobeNewswire
Orchestra BioMed (NASDAQ:OBIO) Shares Down 6.1% – Time to Sell? - Defense World
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - GlobeNewswire
Orchestra BioMed Secures Triple Conference Lineup: CEO Sets Major Investor Presentations - Stock Titan
Analyzing PetVivo (NASDAQ:PETV) & Orchestra BioMed (NASDAQ:OBIO) - Defense World
Orchestra BioMed to Highlight Advancements in Cardiac Therapy at HRS 2025 - MSN
Orchestra BioMed stock holds Buy rating, $12 target from H.C. Wainwright - Investing.com Canada
Financial Metrics Unveiled: Orchestra BioMed Holdings Inc (OBIO)’s Key Ratios in the Spotlight - DWinneX
Orchestra BioMed Secures FDA Breakthrough Device Designation for AVIM Therapy - MSN
When (OBIO) Moves Investors should Listen - news.stocktradersdaily.com
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting - Investing News Network
Orchestra BioMed Hosts Symposium on Breakthrough AVIM Therapy for Uncontrolled Hypertension at HRS 2025 Annual Meeting - Nasdaq
FDA Breakthrough Therapy for 7.7M Hypertension Patients: New Clinical Data | OBIO Stock News - Stock Titan
Examining the Potential Price Growth of Orchestra BioMed Holdings Inc (OBIO) - knoxdaily.com
Investors Take Advantage Of 0.70% Gain In Orchestra BioMed Holdings Inc (NASDAQ: OBIO) - Stocksregister
FDA grants breakthrough status to Orchestra BioMed’s AVIM therapy By Investing.com - Investing.com Canada
Orchestra BioMed Holdings Inc: A Year of Highs, Lows, and Market Resilience - investchronicle.com
There Are Mixed Signals on the Chart for Orchestra BioMed Holdings Inc (OBIO) - uspostnews.com
FDA grants breakthrough status to Orchestra BioMed’s AVIM therapy - Investing.com Australia
Orchestra BioMed shares surge on FDA breakthrough designation By Investing.com - Investing.com Nigeria
Orchestra BioMed (OBIO) Gains FDA Breakthrough Device Status for AVIM Therapy | OBIO Stock News - GuruFocus
Orchestra BioMed shares surge on FDA breakthrough designation - Investing.com Australia
Orchestra BioMed Receives FDA Breakthrough Device Designation for Atrioventricular Interval Modulation Therapy to Address Uncontrolled Hypertension - Nasdaq
Orchestra BioMed (OBIO) Receives FDA Breakthrough Device Designation for AVIM Therapy - StreetInsider
Orchestra's Revolutionary Blood Pressure Device Earns FDA Breakthrough Status: 7.7M Patients Could Benefit - Stock Titan
Orchestra BioMed Reports 2024 Financial Results and Advances Cardiovascular Therapy - MSN
Orchestra BioMed’s Strategic Advances in Medical Innovations - TipRanks
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Orchestra Biomed Holdings Inc Stock (OBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 10% Owner |
Apr 29 '25 |
Buy |
2.53 |
50,000 |
126,500 |
8,256,163 |
| Aryeh Jason | Director |
Dec 27 '24 |
Option Exercise |
4.30 |
11,700 |
50,310 |
80,060 |
| Hochman David P | See Remarks |
Dec 23 '24 |
Buy |
4.66 |
4,000 |
18,640 |
579,498 |
| Taylor Andrew Lawrence | Chief Financial Officer |
Dec 19 '24 |
Buy |
4.83 |
1,000 |
4,830 |
344,960 |
| Hochman David P | See Remarks |
Dec 18 '24 |
Buy |
4.91 |
5,000 |
24,550 |
575,498 |
| Hochman David P | See Remarks |
Sep 25 '24 |
Buy |
4.75 |
7,500 |
35,630 |
335,002 |
| Hochman David P | See Remarks |
Sep 24 '24 |
Buy |
4.91 |
2,500 |
12,275 |
570,498 |
| Sherman Darren | See Remarks |
Sep 09 '24 |
Sale |
5.48 |
6,804 |
37,286 |
772,691 |
| Sherman Darren | See Remarks |
Sep 10 '24 |
Sale |
5.31 |
6,904 |
36,660 |
765,787 |
| Fain Eric S | Director |
Sep 06 '24 |
Sale |
5.64 |
2,000 |
11,280 |
44,810 |
0.47%
2.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):